Total Payments
$19,467
2024 Payments
$167.91
Companies
80
Transactions
1,207
Medicare Patients
10,637
Medicare Billing
$2.2M
Payment Breakdown by Category
Food & Beverage$17,564 (90.2%)
Other$1,048 (5.4%)
Education$855.19 (4.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,564 | 1,180 | 90.2% |
| Long term medical supply or device loan | $1,048 | 11 | 5.4% |
| Education | $855.19 | 16 | 4.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,846 | 59 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,453 | 80 | $0 (2023) |
| PFIZER INC. | $1,219 | 151 | $0 (2023) |
| Janssen Biotech, Inc. | $1,032 | 50 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $974.79 | 92 | $0 (2023) |
| Amgen Inc. | $959.85 | 52 | $0 (2023) |
| Merck Sharp & Dohme LLC | $932.11 | 55 | $0 (2023) |
| Lilly USA, LLC | $905.05 | 76 | $0 (2023) |
| Incyte Corporation | $870.51 | 54 | $0 (2023) |
| Celgene Corporation | $742.48 | 70 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $167.91 | 4 | Novartis Pharmaceuticals Corporation ($83.33) |
| 2023 | $3,066 | 177 | Janssen Biotech, Inc. ($465.77) |
| 2022 | $2,834 | 179 | Merck Sharp & Dohme LLC ($251.87) |
| 2021 | $3,265 | 151 | Novartis Pharmaceuticals Corporation ($1,017) |
| 2020 | $1,825 | 96 | Pacira Pharmaceuticals Incorporated ($231.97) |
| 2019 | $2,964 | 215 | Lilly USA, LLC ($270.47) |
| 2018 | $2,848 | 199 | AstraZeneca Pharmaceuticals LP ($322.48) |
| 2017 | $2,498 | 186 | E.R. Squibb & Sons, L.L.C. ($240.36) |
All Payment Transactions
1,207 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $24.21 | General |
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 08/19/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 05/01/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $38.53 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 11/16/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $23.09 | General |
| Category: Oncology | ||||||
| 11/14/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: Oncology | ||||||
| 11/14/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Oncology | ||||||
| 11/13/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $15.49 | General |
| 11/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.24 | General |
| Category: Hematology | ||||||
| 11/10/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $1.99 | General |
| Category: Hematology | ||||||
| 11/07/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $1.80 | General |
| Category: Oncology | ||||||
| 10/31/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Rare Disease | ||||||
| 10/31/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Rare Disease | ||||||
| 10/28/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Oncology | ||||||
| 10/25/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Oncology | ||||||
| 10/24/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Oncology | ||||||
| 10/24/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Oncology | ||||||
| 10/23/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $20.85 | General |
| Category: Hematology | ||||||
| 10/23/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $0.65 | General |
| Category: Hematology | ||||||
| 10/09/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $21.08 | General |
| Category: Oncology | ||||||
| 10/06/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 2,749 | 24,003 | $1.5M | $406,583 |
| 2022 | 35 | 2,646 | 22,059 | $1.8M | $486,223 |
| 2021 | 38 | 2,702 | 31,366 | $2.3M | $652,714 |
| 2020 | 37 | 2,540 | 107,770 | $2.3M | $632,258 |
Total Patients
10,637
Total Services
185,198
Medicare Billing
$2.2M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 361 | 904 | $302,363 | $86,666 | 28.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 50 | 68 | $243,488 | $78,999 | 32.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 3,120 | $139,464 | $57,822 | 41.5% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 19 | 5,000 | $173,150 | $29,884 | 17.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 49 | 68 | $66,809 | $27,242 | 40.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 34 | 186 | $88,649 | $18,980 | 21.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 99 | $44,214 | $13,743 | 31.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 366 | 1,303 | $18,190 | $10,936 | 60.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 59 | 59 | $37,634 | $10,405 | 27.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 352 | 1,207 | $40,905 | $9,137 | 22.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 331 | 881 | $40,579 | $9,105 | 22.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 11 | 60 | $41,086 | $8,228 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 76 | $17,185 | $5,234 | 30.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 25 | 175 | $18,652 | $3,909 | 21.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 65 | $15,473 | $3,742 | 24.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $12,048 | $3,178 | 26.4% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 79 | 146 | $12,074 | $2,713 | 22.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 38 | 237 | $17,751 | $2,626 | 14.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 49 | $11,556 | $2,436 | 21.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 47 | $10,878 | $2,424 | 22.3% |
| 82248 | Bilirubin level, direct | Office | 2023 | 239 | 464 | $10,148 | $2,278 | 22.4% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 207 | 348 | $9,163 | $2,065 | 22.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 14 | $8,983 | $1,986 | 22.1% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 32 | 40 | $25,945 | $1,519 | 5.9% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 19 | 22 | $9,377 | $1,484 | 15.8% |
About Dr. Edit Tolnai, M.D
Dr. Edit Tolnai, M.D is a Hematology healthcare provider based in Jupiter, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1558358630.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edit Tolnai, M.D has received a total of $19,467 in payments from pharmaceutical and medical device companies, with $167.91 received in 2024. These payments were reported across 1,207 transactions from 80 companies. The most common payment nature is "Food and Beverage" ($17,564).
As a Medicare-enrolled provider, Tolnai has provided services to 10,637 Medicare beneficiaries, totaling 185,198 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Jupiter, FL
- Active Since 10/04/2005
- Last Updated 10/30/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1558358630
Products in Payments
- KISQALI (Drug) $1,115
- KEYTRUDA (Biological) $844.69
- OPDIVO (Biological) $749.16
- TAGRISSO (Drug) $613.25
- DARZALEX (Biological) $590.60
- XTANDI (Drug) $518.15
- CYRAMZA (Drug) $500.33
- IBRANCE (Drug) $382.51
- JAKAFI (Drug) $369.10
- Nplate (Biological) $337.17
- Lenvima (Drug) $318.67
- LYNPARZA (Drug) $303.67
- REBLOZYL (Biological) $291.80
- ADCETRIS (Biological) $280.77
- GILOTRIF (Drug) $273.05
- VERZENIO (Drug) $270.23
- ZEJULA (Drug) $252.75
- IMBRUVICA (Drug) $245.60
- EXPAREL (Drug) $231.97
- Enhertu (Drug) $220.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.